H.C. Wainwright maintained a Buy rating on Lexicon Pharmaceuticals, Inc. (LXRX) on March 05, 2026 and raised the price target to $6. This single-item update is the latest LXRX analyst rating movement and gives investors a clearer short-term reference for valuation.
This article is available in full on our main platform. Get access to complete analysis, stock insights, and more.
Read Full Article →
SLNA stock pre-market update: $0.03 price, heavy volume, Meyka AI forecast and grade for investors
GPKUF stock falls to USD 0.0001 on 14 Jan 2026. Meyka AI forecast and risks for this PNK microcap
Zijin Gold International IPO (2259.HK) surges over 90% in Hong Kong’s grey market, signaling strong investor interest in the gold sector.
Gold silver prices swing as GLD drops after record highs. UK-focused take on drivers, today’s moves, and next catalysts. Actionable levels, risks, and portfolio tips.
MetaMask TRON support goes live, enabling TRX and TRC‑20 USDT transfers in-app. What it means for ETHUSD, DeFi liquidity, and Canadian investors. Signals, risks, and outlook.
After-hours: DBK.SW stock at CHF27.50 on 19 Feb 2026; Meyka model shows **26.01%** upside